Aetion, a NYC-based healthcare technology company, raised $110m in Series C funding.
The round was led by Warburg Pincus, with participation from B Capital and Foresite Capital and existing backers New Enterprise Associates (NEA) and Flare Capital Partners.
The company will use the new funds to extend the capabilities of its Aetion Evidence Platform®, expand its European and Asian-Pacific presence, and grow its commercial team.
Led by CEO Carolyn Magill, Aetion delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. It informs health care’s decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation.
The Aetion Evidence Platform is used by the majority of the top global biopharma firms, leading payers, and regulatory and HTA agencies to inform decisions on the safety, effectiveness, and value of medical products.